3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.

Three-dimensional quantitative structure-activity relationship (3D-QSAR) models were developed using comparative molecular field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA) on a series of agonists of thyroid hormone receptor beta (TRbeta), which may lead to safe therapies for non-thyroid disorders while avoiding the cardiac side effects. The reasonable q(2) (cross-validated) values 0.600 and 0.616 and non-cross-validated r(2) values of 0.974 and 0.974 were obtained for CoMFA and CoMSIA models for the training set compounds, respectively. The predictive ability of two models was validated using a test set of 12 molecules which gave predictive correlation coefficients (r(pred)(2)) of 0.688 and 0.674, respectively. The Lamarckian Genetic Algorithm (LGA) of AutoDock 4.0 was employed to explore the binding mode of the compound at the active site of TRbeta. The results not only lead to a better understanding of interactions between these agonists and the thyroid hormone receptor beta but also can provide us some useful information about the influence of structures on the activity which will be very useful for designing some new agonist with desired activity.

[1]  M. Gottardis,et al.  Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. , 1998, Cancer research.

[2]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[3]  Markus A. Lill,et al.  Simulating α/β Selectivity at the Human Thyroid Hormone Receptor: Consensus Scoring Using Multidimensional QSAR , 2007 .

[4]  Peter Cornelius,et al.  Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. , 2003, Bioorganic & medicinal chemistry letters.

[5]  J. C. Emmett,et al.  A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity , 1986, Nature.

[6]  G. Grover,et al.  Recent Advances in the Development of Agonists Selective for β1-Type Thyroid Hormone Receptor , 2007 .

[7]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[8]  L. Ye,et al.  Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. , 2003, Journal of medicinal chemistry.

[9]  Paola Gramatica,et al.  QSAR study of selective ligands for the thyroid hormone receptor beta. , 2007, Bioorganic & medicinal chemistry.

[10]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[11]  D. Forrest,et al.  Functions of thyroid hormone receptors in mice. , 2000, Thyroid : official journal of the American Thyroid Association.

[12]  G. Grover,et al.  Selective thyroid hormone agonists: A strategy for treating metabolic syndrome , 2005 .

[13]  Johan Malm,et al.  Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. , 2004, Bioorganic & medicinal chemistry letters.

[14]  J. Baxter,et al.  Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. , 2002, Journal of medicinal chemistry.

[15]  S. Refetoff,et al.  Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. , 1992, The Journal of clinical endocrinology and metabolism.

[16]  E. C. Jorgensen,et al.  Comparative effects of 3,5-dimethyl-3'-isopropyl-L-thyronine (DIMIT) and 3,5-diiodo-3'-isopropylthyroacetic acid (IpTA2) on body weight gain and lipid metabolism in genetically obese Zucker rats. , 1986, Biochemical pharmacology.

[17]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[19]  M. Lazar.  Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.

[20]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[21]  Johan Malm,et al.  Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[22]  라발 사우린케이.,et al.  Thyroid receptor ligands , 2009 .

[23]  J. Malm.  Thyroid hormone ligands and metabolic diseases. , 2004, Current pharmaceutical design.

[24]  H P Koeffler,et al.  Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. , 1999, Blood.

[25]  Bruce R. Kowalski,et al.  Chemometrics, mathematics and statistics in chemistry , 1984 .

[26]  Johan Malm,et al.  Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[27]  Grazia Chiellini,et al.  Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Fanjul,et al.  Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. , 1998, Cancer research.

[29]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[30]  Markus A Lill,et al.  The challenge of predicting drug toxicity in silico. , 2006, Basic & clinical pharmacology & toxicology.

[31]  Prediction of binding affinities to beta1 isoform of human thyroid hormone receptor by genetic algorithm and projection pursuit regression. , 2007, Bioorganic & medicinal chemistry letters.

[32]  B J Hoffer,et al.  Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.

[33]  A. Catapano,et al.  Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. , 1986, Atherosclerosis.

[34]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[35]  Peter Brandt,et al.  Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. , 2006, Journal of medicinal chemistry.

[36]  R. Eaton,et al.  The effects of altered thyroid status on lipid metabolism in the genetic hyperlipemic Zucker rat. , 1981, Atherosclerosis.

[37]  E. Kuipers.  Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? , 2006, Basic & clinical pharmacology & toxicology.

[38]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[39]  Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. , 2007, Bioorganic & medicinal chemistry letters.

[40]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[41]  P. Nilsson-ehle,et al.  Experimental Hyperthyroidism in Man: Effects on Plasma Lipoproteins, Lipoprotein Lipase and Hepatic Lipase , 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.